> top > docs > PubMed:11751483 > annotations

PubMed:11751483 JSONTXT

Annnotations TAB JSON ListView MergeView

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-183 Sentence denotes A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.
TextSentencer_T2 184-192 Sentence denotes PURPOSE:
TextSentencer_T3 193-401 Sentence denotes Bcl-2 is a negative prognostic indicator in prostate cancer, implicated in the development of androgen independence and treatment resistance, and is overexpressed in hormone-refractory prostate cancer (HRPC).
TextSentencer_T4 402-704 Sentence denotes Genasense is a phosphorothioate antisense oligonucleotide complementary to the bcl-2 mRNA open reading frame that in preclinical studies has shown significant activity in inhibiting expression of Bcl-2, delaying androgen independence, and improving chemosensitivity in prostate and other cancer models.
TextSentencer_T5 705-843 Sentence denotes In this dose escalation study, we evaluated the combination of Genasense and mitoxantrone, a standard chemotherapy for patients with HRPC.
TextSentencer_T6 844-851 Sentence denotes DESIGN:
TextSentencer_T7 852-1026 Sentence denotes Twenty-six patients with HRPC were treated at seven dose levels receiving Genasense at a dose ranging from 0.6 to 5.0 mg/kg/day and mitoxantrone from 4 mg/m(2) to 12 mg/m(2).
TextSentencer_T8 1027-1155 Sentence denotes Genasense was administered as a 14-day i.v. continuous infusion every 28 days with mitoxantrone given as an i.v. bolus on day 8.
TextSentencer_T9 1156-1164 Sentence denotes RESULTS:
TextSentencer_T10 1165-1207 Sentence denotes No dose-limiting toxicities were observed.
TextSentencer_T11 1208-1308 Sentence denotes Hematological toxicities were transient and included neutropenia, thrombocytopenia, and lymphopenia.
TextSentencer_T12 1309-1465 Sentence denotes Nonhematological toxicities included fatigue, fever, nausea, arthralgias, myalgias, and transient elevations in serum creatinine, none of which were severe.
TextSentencer_T13 1466-1528 Sentence denotes Two patients had >50% reductions in prostate-specific antigen.
TextSentencer_T14 1529-1686 Sentence denotes One patient, who received six cycles of Genasense at 1.2 mg/kg/day and a low dose (4 mg/m(2)) of mitoxantrone, also had symptomatic improvement in bone pain.
TextSentencer_T15 1687-1882 Sentence denotes Peripheral blood lymphocyte Bcl-2 protein expression decreased in five of five patients given Genasense at 5mg/kg/day (mean change from baseline, -12.8%; SD, 16.4%) as assessed by flow cytometry.
TextSentencer_T16 1883-1981 Sentence denotes Serum concentrations of Genasense given at doses of 3 mg/kg/day and greater, exceeded 1 microg/ml.
TextSentencer_T17 1982-1994 Sentence denotes CONCLUSIONS:
TextSentencer_T18 1995-2194 Sentence denotes Genasense and mitoxantrone are well tolerated in combination, and mitoxantrone can be delivered at a standard dose with biologically active doses of Genasense without significant additional toxicity.
TextSentencer_T19 2195-2343 Sentence denotes This observation allays concerns about trials that combine Genasense with full doses of other cytotoxic agents seeking greater evidence of activity.
T1 0-183 Sentence denotes A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.
T2 184-192 Sentence denotes PURPOSE:
T3 193-401 Sentence denotes Bcl-2 is a negative prognostic indicator in prostate cancer, implicated in the development of androgen independence and treatment resistance, and is overexpressed in hormone-refractory prostate cancer (HRPC).
T4 402-704 Sentence denotes Genasense is a phosphorothioate antisense oligonucleotide complementary to the bcl-2 mRNA open reading frame that in preclinical studies has shown significant activity in inhibiting expression of Bcl-2, delaying androgen independence, and improving chemosensitivity in prostate and other cancer models.
T5 705-843 Sentence denotes In this dose escalation study, we evaluated the combination of Genasense and mitoxantrone, a standard chemotherapy for patients with HRPC.
T6 844-851 Sentence denotes DESIGN:
T7 852-1026 Sentence denotes Twenty-six patients with HRPC were treated at seven dose levels receiving Genasense at a dose ranging from 0.6 to 5.0 mg/kg/day and mitoxantrone from 4 mg/m(2) to 12 mg/m(2).
T8 1027-1155 Sentence denotes Genasense was administered as a 14-day i.v. continuous infusion every 28 days with mitoxantrone given as an i.v. bolus on day 8.
T9 1156-1164 Sentence denotes RESULTS:
T10 1165-1207 Sentence denotes No dose-limiting toxicities were observed.
T11 1208-1308 Sentence denotes Hematological toxicities were transient and included neutropenia, thrombocytopenia, and lymphopenia.
T12 1309-1465 Sentence denotes Nonhematological toxicities included fatigue, fever, nausea, arthralgias, myalgias, and transient elevations in serum creatinine, none of which were severe.
T13 1466-1528 Sentence denotes Two patients had >50% reductions in prostate-specific antigen.
T14 1529-1686 Sentence denotes One patient, who received six cycles of Genasense at 1.2 mg/kg/day and a low dose (4 mg/m(2)) of mitoxantrone, also had symptomatic improvement in bone pain.
T15 1687-1882 Sentence denotes Peripheral blood lymphocyte Bcl-2 protein expression decreased in five of five patients given Genasense at 5mg/kg/day (mean change from baseline, -12.8%; SD, 16.4%) as assessed by flow cytometry.
T16 1883-1981 Sentence denotes Serum concentrations of Genasense given at doses of 3 mg/kg/day and greater, exceeded 1 microg/ml.
T17 1982-1994 Sentence denotes CONCLUSIONS:
T18 1995-2194 Sentence denotes Genasense and mitoxantrone are well tolerated in combination, and mitoxantrone can be delivered at a standard dose with biologically active doses of Genasense without significant additional toxicity.
T19 2195-2343 Sentence denotes This observation allays concerns about trials that combine Genasense with full doses of other cytotoxic agents seeking greater evidence of activity.

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
11751483-0#69#74#gene596 69-74 gene596 denotes Bcl-2
11751483-0#148#182#diseaseC1328504 148-182 diseaseC1328504 denotes hormone-refractory prostate cancer
11751483-1#0#5#gene596 193-198 gene596 denotes Bcl-2
11751483-1#44#59#diseaseC0376358 237-252 diseaseC0376358 denotes prostate cancer
11751483-1#44#59#diseaseC0600139 237-252 diseaseC0600139 denotes prostate cancer
69#74#gene596148#182#diseaseC1328504 11751483-0#69#74#gene596 11751483-0#148#182#diseaseC1328504 associated_with Bcl-2,hormone-refractory prostate cancer
0#5#gene59644#59#diseaseC0376358 11751483-1#0#5#gene596 11751483-1#44#59#diseaseC0376358 associated_with Bcl-2,prostate cancer
0#5#gene59644#59#diseaseC0600139 11751483-1#0#5#gene596 11751483-1#44#59#diseaseC0600139 associated_with Bcl-2,prostate cancer

performance-test

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 1698-1703 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
PD-UBERON-AE-B_T2 1421-1426 http://purl.obolibrary.org/obo/UBERON_0001977 denotes serum
PD-UBERON-AE-B_T3 1883-1888 http://purl.obolibrary.org/obo/UBERON_0001977 denotes Serum

DisGeNet-2017-sample

Id Subject Object Predicate Lexical cue
T1923 193-198 gene:596 denotes Bcl-2
T1924 237-252 disease:C0376358 denotes prostate cancer
R1 T1923 T1924 associated_with Bcl-2,prostate cancer
R2 T1923 T1924 associated_with Bcl-2,prostate cancer

UBERON-AE

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 1421-1426 http://purl.obolibrary.org/obo/UBERON_0001977 denotes serum
PD-UBERON-AE-B_T2 1698-1703 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood

DisGeNET

Id Subject Object Predicate Lexical cue
T0 69-74 gene:596 denotes Bcl-2
T1 148-182 disease:C1328504 denotes hormone-refractory prostate cancer
T2 193-198 gene:596 denotes Bcl-2
T3 395-399 disease:C1328504 denotes HRPC
T4 193-198 gene:596 denotes Bcl-2
T5 237-252 disease:C0376358 denotes prostate cancer
T6 193-198 gene:596 denotes Bcl-2
T7 359-393 disease:C1328504 denotes hormone-refractory prostate cancer
T8 193-198 gene:596 denotes Bcl-2
T9 237-252 disease:C0600139 denotes prostate cancer
T10 481-486 gene:596 denotes bcl-2
T11 690-696 disease:C1306459 denotes cancer
T12 481-486 gene:596 denotes bcl-2
T13 690-696 disease:C0006826 denotes cancer
R1 T0 T1 associated_with Bcl-2,hormone-refractory prostate cancer
R2 T2 T3 associated_with Bcl-2,HRPC
R3 T4 T5 associated_with Bcl-2,prostate cancer
R4 T6 T7 associated_with Bcl-2,hormone-refractory prostate cancer
R5 T8 T9 associated_with Bcl-2,prostate cancer
R6 T10 T11 associated_with bcl-2,cancer
R7 T12 T13 associated_with bcl-2,cancer